The exquisite specificity of TCR4, combined with (1) the tumor-specific expression of Mut PIK3CA and (2) the absence of a stable pWT/HLA complex on normal tissues, establishes a favorable safety profile for this receptor’s potential as a clinical candidate. This evidence concerns the gene PIK3CA and neoplasm.